目的 :观察拉米夫定治疗乙型肝炎相关的失代偿性肝硬化的安全性和有效性。方法 :选择乙型肝炎相关的失代偿性肝硬化患者 3例 ,在综合治疗的基础上加用拉米夫定 10 0 mg,观察拉米夫定治疗前后患者的临床症状、肝脏功能和肝脏B超的变化。结果 :患者加用拉米夫定治疗 3个月后出现临床症状和肝脏功能的显著改善 ,最大改善出现在治疗开始后 6～ 9个月 ,但肝脏 B超无显著变化。拉米夫定治疗无明显不良反应。结论 :拉米夫定可安全用于乙型肝炎相关的失代偿性肝硬化的治疗 ,并使患者获得缓慢而显著的临床和生化改善 ,但是否可降低门脉压力 ,还需长期观察 Objective: To observe the safety and efficacy of lamivudine in the treatment of hepatitis B-related decompensated cirrhosis. Methods: Three patients with hepatitis B related decompensated cirrhosis were selected. On the basis of comprehensive treatment, 10 mg of lamivudine was added to observe the clinical symptoms, liver function and liver function of patients before and after lamivudine treatment B-change. Results: After 3 months of treatment with lamivudine, clinical symptoms and liver function were significantly improved. The greatest improvement occurred 6 to 9 months after the start of treatment, but there was no significant change in liver B ultrasound. No significant adverse reactions Lamivudine treatment. Conclusions: Lamivudine is safe for use in the treatment of hepatitis B-related decompensated cirrhosis and provides patients with a slow but significant clinical and biochemical improvement but whether long-term monitoring of portal pressure is required